About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact. Recruitment Fraud Alert Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit. We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.

Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat. After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/2XXw9w3 For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Leading with purpose. Every day. “Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.” Emil D. Kakkis, M.D., Ph.D. Chief Executive Officer and President We have an inclusive culture of value and respect. Ultragenyx brings novel products to those living with rare and ultrarare diseases with a focus on debilitating genetic diseases. Founded in 2010, we have rapidly built a diverse portfolio of approved therapies and products aimed at diseases with a high unmet medical need for which many have no approved therapies. It takes courage, care, talent, and dedication to make a meaningful impact for those living with rare diseases, their families and the rare disease community. We put our people first, so they can take care of the rare disease community. We purposefully cultivate and nurture a dynamic, supportive work environment where we encourage every team member to share their new ideas and help us unlock more possibilities. Our team is made up of exceptional and diverse people with a strong passion and commitment to helping those living with rare diseases. By embracing generosity, curiosity, inclusion, and humility we are constantly learning together—fostering an environment that supports profound growth and fulfillment. If you want to have a meaningful impact, do the best work of your career while having fun and growing professionally and personally, come join our team! Visit our community guidelines at: https://ultragenyx.co/community

Amyris is a vertically integrated, synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms. Leveraging two decades of experience, Amyris collaborates with companies to co-create innovative ingredients at unprecedented speed and scale. This enables partners to deliver products with differentiated performance that meet sustainability and economic objectives. Its renewable and traceable ingredients are included in over 20,000 products from the world’s top brands, reaching more than 300 million consumers. For more information, please visit http://www.amyris.com.

Garratt-Callahan Company is one of the leading providers of expert industrial water treatment solutions. Offering comprehensive water treatment solutions and expert consulting services backed by 117+ years of experience, we optimize system performance to extend equipment life, reduce health and safety risks, and minimize operating costs. We are guided by our responsibility to provide our customers with unparalleled customer service and effective, dependable water treatment solutions. Garratt-Callahan takes a proactive scientific approach to prevent problems before they occur so that our customers can spend more time running their business and less time trying to fix it. Specialties We utilize the most current, proven technology and treat our customers’ facilities with the same care and conscientiousness that we would with our own. We offer a full range of chemical and equipment solutions, created in our certified laboratory that follows State and Federal EPA standards. We also ensure that our water treatment products are certified in compliance with the international standards of quality of ISO 9001:2015 by NSF-ISR. Our water treatment services include: * Boiler Water Treatment * Cooling Water Treatment * Wastewater Solutions * LAP Certified In-house Laboratory * Water Management Plans * Legionella Mitigation * Secondary Disinfection * Water Treatment Training ASSE/IAPMO/ANSI 12080 Water Safety Training With the global COVID-19 pandemic and virus variants, water safety is even more critical. Our team is trained and certified with the implementation of ASHRAE 188-2018 to minimize the risk of Legionellosis. In 2020, ASHRAE adopted the American Society of Sanitary Engineers (ASSE) 10280. A growing number of our field technicians are certified under the new ASSE 12080 program.

Method Products is part of Lifestyle Brands (the LSB), a growing house of like-minded brands under the SC Johnson umbrella including Method, Mrs. Meyer’s Clean Day, Babyganics and Ecover. Headquartered in San Francisco with additional operations in Chicago and throughout Europe, the LSB is home to 650 employees. Together we act as a force for bold, transformative growth with a focus on delivering positive impact for people and the planet. At the LSB we imagine the world that we want, then set out to create it. We do things differently, because we’re out to make a difference. If you’re into pioneering the future and doing good while doing business, come join us. The LSB is part of SC Johnson, a family-owned company and leading manufacturer of household cleaning, home storage, air care, pest control and shoe care products, as well as professional products. Originally founded in 1886 and headquartered in Wisconsin, U.S.A., SC Johnson and the Lifestyle Brands division are at work for a better world. For career opportunities with SC Johnson Lifestyle Brands, please visit jobs.scjlifestylebrands.com or https://www.linkedin.com/company/scj-lifestyle-brands/ on LinkedIn.

We are Sila—a next generation battery materials company dedicated to accelerating energy transformation for a more sustainable future. Our next-gen anode material is the first significant chemistry improvement to lithium-ion batteries to reach the market in 30 years. Our silicon anode material is a simple drop-in replacement to graphite and significantly boosts the energy density of lithium-ion batteries without compromising performance. Today, Sila science powers innovative consumer electronics. Tomorrow, it will fuel our EV future and the electrification of everything. We work directly with leading consumer electronics and automotive OEMs to help accelerate product roadmaps, and partners with battery manufacturers commercial cell production. Our partners include BMW, Daimler, and ATL. Sila Nano’s first products significantly increase the energy density of state-of-the-art lithium-ion batteries. Our materials are manufacturable economically at scale and are drop-in replacements to existing battery manufacturing processes.

XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

K2 Pure Solutions helps provide an answer to eliminating the need to transport chlorine for water purification and disinfection, as well as other industries, by deploying and funding a North American wide network of state-of-the-art facilities utilizing inherently safe technology. For more information, please visit: www.k2pure.com

We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.